As global markets respond to China's stimulus measures and European indices show signs of recovery, Sweden's economic landscape is also experiencing shifts, highlighted by the Riksbank's recent interest rate cut. In this context, investors are increasingly looking for opportunities in stocks that may be trading below their intrinsic value, offering potential for growth as market conditions stabilize. Identifying such undervalued stocks involves assessing factors like strong fundamentals and resilience amidst current economic trends.
Name | Current Price | Fair Value (Est) | Discount (Est) |
CTT Systems (OM:CTT) | SEK268.00 | SEK493.60 | 45.7% |
Concentric (OM:COIC) | SEK217.00 | SEK406.77 | 46.7% |
Biotage (OM:BIOT) | SEK184.70 | SEK363.63 | 49.2% |
Lindab International (OM:LIAB) | SEK279.20 | SEK528.97 | 47.2% |
Nolato (OM:NOLA B) | SEK52.10 | SEK98.69 | 47.2% |
Mentice (OM:MNTC) | SEK27.20 | SEK51.00 | 46.7% |
Tourn International (OM:TOURN) | SEK8.82 | SEK16.49 | 46.5% |
Nexam Chemical Holding (OM:NEXAM) | SEK4.07 | SEK7.92 | 48.6% |
MilDef Group (OM:MILDEF) | SEK84.50 | SEK160.69 | 47.4% |
Lyko Group (OM:LYKO A) | SEK116.80 | SEK217.24 | 46.2% |
Click here to see the full list of 44 stocks from our Undervalued Swedish Stocks Based On Cash Flows screener.
Underneath we present a selection of stocks filtered out by our screen.
Overview: Biotage AB (publ) offers solutions and products for drug discovery and development, analytical testing, and water and environmental testing, with a market cap of SEK 14.84 billion.
Operations: The company's revenue segments include Healthcare Software, which generated SEK 2.08 billion.
Estimated Discount To Fair Value: 49.2%
Biotage is trading at SEK184.7, significantly below its estimated fair value of SEK363.63, suggesting it is undervalued based on discounted cash flows. Earnings are projected to grow 20.4% annually, outpacing the Swedish market's 15.2% growth forecast, while revenue is expected to increase by 11.1%. Recent executive changes with Frederic Vanderhaegen as CEO and M&A rumors involving KKR's stake add strategic interest amidst strong financial performance in recent quarters.
Overview: Fortnox AB (publ) offers financial and administrative software solutions for small and medium-sized businesses, accounting firms, and organizations, with a market cap of approximately SEK38.55 billion.
Operations: The company's revenue is derived from various segments including Core Products (SEK734 million), Businesses (SEK378 million), Accounting Firms (SEK352 million), Marketplaces (SEK160 million), and Financial Services (SEK249 million).
Estimated Discount To Fair Value: 25.7%
Fortnox's stock is trading at SEK63.2, below its estimated fair value of SEK85.05, reflecting a potential undervaluation based on discounted cash flows. The company's earnings grew by 48.1% over the past year and are forecast to grow 22.24% annually, surpassing the Swedish market's growth rate of 15.2%. Revenue is projected to increase by 20% per year, significantly higher than the market average of 1.4%, highlighting strong future prospects.
Overview: HMS Networks AB (publ) provides products that facilitate communication and information sharing for industrial equipment globally, with a market cap of SEK19.82 billion.
Operations: The company's revenue segment includes Wireless Communications Equipment, which generated SEK3.01 billion.
Estimated Discount To Fair Value: 26.7%
HMS Networks is trading at SEK395, significantly below its estimated fair value of SEK539.21, indicating a potential undervaluation based on cash flows. Despite a high debt level and recent shareholder dilution, earnings are forecast to grow substantially at 28.4% annually, outpacing the Swedish market's growth rate of 15.2%. Revenue is expected to rise by 15.3% per year; however, net profit margins have decreased from 20.1% to 14%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OM:BIOT OM:FNOX and OM:HMS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.